Generation of monoclonal antibody targeting fibroblast growth factor receptor 3

Hybridoma

Volumn 28, Issue 4, 2009, Pages 295-300

  Gorbenko, Olena ^a   Ovcharenko, Galyna ^a   Klymenko, Tetyana ^a   Zhyvoloup, Olexandr ^a   Gaman, Nadia ^a   Volkova, Darija ^a   Gout, Ivan ^a,b   Filonenko, Valeriy ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MONOCLONAL ANTIBODY; SERINE;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BACTERIUM; BLADDER CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNIZATION; IMMUNOPRECIPITATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYBRIDOMAS; INSECTS; MICE; MICE, INBRED BALB C; MUTATION; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION;

EID: 68949144552     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0018     Document Type: Article

References (28)

1. Ornitz DM, and Itoh N: Fibroblast growth factors. Genome Biol 2001;2:3005.1-5.12.
2. Givol D, Eswarakumar VP, and Lonai P: Molecular and cellular biology of FGF signaling. In: Inborn Errors of Development - The Molecular Basis of Clinical Disorders of Morphogenesis. Epstein CJ, Erickson RP, and Wynshaw-Boris A (Eds). Oxford University Press, London, 2003, pp.367-379.
3. Jaye M, Schlessinger J, and Dionne CA: Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta 1992;1135:185-199.
4. Sleeman M, Fraser J, McDonald M, Yuan S, White D, Grandison P, Kumble K, Watson JD, and Murison JG: Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001;271:171-182.
5. Powers CJ, McLeskey SW, and Wellstein A: Fibroblast growth factors, their receptors and signaling: Endocr Relat Cancer 2000;7:165-197.
6. Chellaiah A, Yuan W, Chellaiah M, and Ornitz DM: Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem 1999;274:34785-34794.
7. Thompson LM, Plummer S, Schalling M, Altherr MR, Gusella JF, Housman DE, and Wasmuth JJ: A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics 1991;11:1133-1142.
8. Perez-Castro AV, Wilson J, and Altherr MR: Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997;41:10-16.
9. Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, and Kurokawa-Seo M: A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 2001;276:11031-11040.
10. Scotet E, and Houssaint E: The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim Biophys Acta 1995;1264:238-242.
11. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, and Ornitz DM: Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-15700.
12. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, and Mohammadi M: Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 2000;6:743-750.
13. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, and Lax I: Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;79:1015-1024.
14. Ong SH, Guy GR, Hadari YR, Laks S, Gotoh N, Schlessinger J, and Lax I: FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 2000;20:979-989.
15. L'Hôte CG, and Knowles MA: Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304:417-431.
16. Muenke M, and Schell U: Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995;11:308-313.
17. Webster MK, and Donoghue DJ: FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997;13:178-182.
18. Hafner C, Hartmann A, Landthaler M, and Vogt T: FGFR3 mutations in benign skin tumors. Cell Cycle 2006;23:2723-2728.
19. Li E, and Hristova K: Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 2006;45:6241-6251.
20. Eswarakumar VP, Lax I, and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-149.
21. Sibley K, Stern P, and Knowles MA: Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001;20:4416-8.26.
22. Van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, and Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of super-ficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-1268.
23. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, and Bergsagel PL: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97:729-736.
24. Knowles MA: Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25:581-593.
25. Cappellen D, De Oliveira C, Ricol D, Gil Diez de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, and Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet 1999;23:18-20.
26. Grand EK, Chase AJ, Heath C, Rahemtulla A, and Cross NC: Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004;18:962-966.
27. Capdeville R, Silberman S, and Dimitrijevic S: Imatinib: the first 3 years. Eur J Cancer 2002;38:77-82.
28. Mir O, Berveiller P, and Pons G: Trastuzumab - mechanism of action and use. N Engl J Med 2007;357:1664-1665.